- Home
- PCRX vs CTO Comparison
PCRX vs CTO Comparison
Compare PCRX & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- CTO
- Stock Information
- Founded
- PCRX 2006
- CTO 1902
- Country
- PCRX United States
- CTO United States
- Employees
- PCRX N/A
- CTO N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- PCRX Health Care
- CTO Real Estate
- Exchange
- PCRX Nasdaq
- CTO Nasdaq
- Market Cap
- PCRX 1.2B
- CTO 568.5M
- IPO Year
- PCRX 2011
- CTO N/A
- Fundamental
- Price
- PCRX $22.90
- CTO $17.66
- Analyst Decision
- PCRX Buy
- CTO Strong Buy
- Analyst Count
- PCRX 8
- CTO 3
- Target Price
- PCRX $28.38
- CTO $22.33
- AVG Volume (30 Days)
- PCRX 525.8K
- CTO 413.6K
- Earning Date
- PCRX 07-29-2025
- CTO 07-29-2025
- Dividend Yield
- PCRX N/A
- CTO 8.63%
- EPS Growth
- PCRX N/A
- CTO N/A
- EPS
- PCRX N/A
- CTO N/A
- Revenue
- PCRX $702,772,000.00
- CTO $132,203,000.00
- Revenue This Year
- PCRX $7.92
- CTO $20.11
- Revenue Next Year
- PCRX $11.02
- CTO $8.51
- P/E Ratio
- PCRX N/A
- CTO N/A
- Revenue Growth
- PCRX 3.08
- CTO 17.48
- 52 Week Low
- PCRX $11.16
- CTO $16.12
- 52 Week High
- PCRX $27.64
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- PCRX 35.82
- CTO 44.45
- Support Level
- PCRX $22.82
- CTO $17.11
- Resistance Level
- PCRX $23.83
- CTO $17.57
- Average True Range (ATR)
- PCRX 0.74
- CTO 0.37
- MACD
- PCRX -0.02
- CTO -0.01
- Stochastic Oscillator
- PCRX 6.22
- CTO 42.58
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.